Atossa Therapeutics (ATOS) Stock Overview
A clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ATOS Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Atossa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.37 |
| 52 Week High | US$19.35 |
| 52 Week Low | US$1.70 |
| Beta | 1.25 |
| 1 Month Change | -46.14% |
| 3 Month Change | -52.02% |
| 1 Year Change | -83.16% |
| 3 Year Change | -87.26% |
| 5 Year Change | -96.49% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.8% | -2.4% | 0.7% |
| 1Y | -83.2% | 35.9% | 20.6% |
Return vs Industry: ATOS underperformed the US Biotechs industry which returned 36.1% over the past year.
Return vs Market: ATOS underperformed the US Market which returned 19.5% over the past year.
Price Volatility
| ATOS volatility | |
|---|---|
| ATOS Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ATOS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATOS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 16 | Steve Quay | www.atossatherapeutics.com |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. Fundamentals Summary
| ATOS fundamental statistics | |
|---|---|
| Market cap | US$20.32m |
| Earnings (TTM) | -US$37.64m |
| Revenue (TTM) | n/a |
Is ATOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATOS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.64m |
| Earnings | -US$37.64m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 20:06 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atossa Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Pooya Hemami | Edison Investment Research |
| Jason McCarthy | Maxim Group |